Fujian Tumor Hospital Trials

Fujian Tumor Hospital	Welcome, Profile Billing Logout

39 Trials

Active Trials Industry lead sponsorIndustry collaborator

Export

Trial + Data / Events

Status

Region

Interventions

Sponsor

Conditions

Primary compl

Study compl

Zhou, Dong

NCT05058482: Non-adhesive Liquid Embolic System in the Embolization of Cerebral Arteriovenous Malformations

Recruiting

N/A

116

RoW

embolism

Suzhou Hengruihongyuan Medical Technology Co. LTD

Intracranial Arteriovenous Malformations

10/23

10/24

NCT04737837: A Real World Study on the Efficacy and Safety of Lacosamide as Add-on Therapy for Focal-onset Epilepsy

Not yet recruiting

N/A

200

RoW

lacosamide, Xinkang

Jiangxi Qingfeng Pharmaceutical Co. Ltd.

Epilepsy, Focal-Onset Seizure

11/21

02/22

yang, jianwei

ENREACH-PDAC-01, NCT05149326: KN046 in Subjects With Advanced Pancreatic Ductal Adenocarcinoma.

Active, not recruiting

408

RoW

KN046, placebo

Jiangsu Alphamab Biopharmaceuticals Co., Ltd

Advanced Pancreatic Ductal Adenocarcinoma

04/24

08/24

G-HOPE-001, NCT06238843: A Multicenter, Phase 3 Study of IBI343 Monotherapy Versus Treatment of Investigator's Choice in Subjects With Previously Treated, Claudin (CLDN) 18.2-positive, HER2-negative, Gastric or Gastroesophageal Junction Adenocarcinoma

Enrolling by invitation

450

RoW

irinotecan, IBI343, paclitaxel

Innovent Biologics (Suzhou) Co. Ltd.

Unresectable or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma

12/26

12/27

NCT05019794: Infigratinib in Subjects With GC or GEJ With FGFR2 Amplification or Other Solid Tumors With Other FGFR Alterations

	NMPA cleared CTA to conduct the Phase 2a trial for metastatic gastric cancer or GE junction adenocarcinoma with FGFR2 gene amplification
	Dec 2020 - Dec 2020: NMPA cleared CTA to conduct the Phase 2a trial for metastatic gastric cancer or GE junction adenocarcinoma with FGFR2 gene amplification

Recruiting

RoW

Infigratinib, BGJ398

LianBio LLC

Gastric Cancer, Gastroesophageal Junction Adenocarcinoma, Solid Tumor

12/22

12/23

NAUTICALCRC, NCT05004350: A Study Evaluating the Combination of Encorafenib and Cetuximab Versus Irinotecan/Cetuximab or Infusional 5-fluorouracil (5-FU)/Folinic Acid (FA)/Irinotecan (FOLFIRI)/Cetuximab in Chinese Patients With BRAF V600E Mutant Metastatic Colorectal Cancer.

Completed

107

RoW

Encorafenib, Braftovi®, PF-07263896, W0090, LGX818, ONO-7702, Cetuximab, Erbitux®, C225, FOLFIRI, Folinic acid + Fluorouracil + Irinotecan

Pierre Fabre Medicament, Merck KGaA, Darmstadt, Germany

BRAF V600E, Metastatic Colorectal Cancer

12/23

12/24

SPH5030-201, NCT06434597: A Clinical Study of SPH5030 Tablets in the Treatment of Her2-positive/Mutated Biliary Tract OR Colorectal Cancer Patients.

Recruiting

RoW

SPH5030

Shanghai Pharmaceuticals Holding Co., Ltd

Biliary Tract or Colorectal Cancer With Her2-positive/Mutated

12/26

NCT05879055: A Study of PM8002 in Combination With Chemotherapy in Patients With NEN

Recruiting

RoW

PM8002, FOLFIRI

Biotheus Inc.

Neuroendocrine Neoplasm

01/27

01/28

KL264-01, NCT04152499: Phase I-II, FIH, TROP2 ADC, Advanced Unresectable/Metastatic Solid Tumors, Refractory to Standard Therapies

Active, not recruiting

1/2

1410

Canada, US, RoW

SKB264, MK-2870, Sacituzumab Tirumotecan (Sac-TMT)

Klus Pharma Inc.

Epithelial Ovarian Cancer, Gastric Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma, Urothelial Carcinoma, Non-Small Cell Lung Cancer, Small-Cell Lung Cancer, Endometrial Carcinoma, Head and Neck Squamous Cell Carcinoma, Breast Cancer, Cervical Cancer

12/25

07/26

KYM901, NCT04805307: Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy, Phase 1 Study of CMG901

Completed

176

RoW

CMG901

Keymed Biosciences Co.Ltd

Advanced Solid Tumor, Gastric Cancer(Including Gastroesophageal Junction Adenocarcinoma), Pancreatic Cancer

04/24

CIBI343A101, NCT05458219: A First-in-human Study of IBI343 in Subjects With Locally Advanced Unresectable or Metastatic Solid Tumors

Recruiting

470

US, RoW

IBI343

Innovent Biologics (Suzhou) Co. Ltd., Fortvita Biologics (USA)Inc., TigerMed

Locally Advanced Unresectable or Metastatic Solid Tumors

12/25

CIBI363A103, NCT06468098: A Study of IBI363 in Subjects With Advanced Malignancies

Recruiting

556

RoW

IBI363 + chemotherapy, IBI363 + Investigator's Choice SOC

Innovent Biologics (Suzhou) Co. Ltd.

Advanced Malignancies

06/25

12/26

NCT05946226: A Phase I Trial to Evaluate the Safety of IMC002 in Advanced Digestive System Tumors

Recruiting

RoW

IMC002 injection, Autologous Claudin 18.2 specific CAR-T cell injection

Suzhou Immunofoco Biotechnology Co., Ltd

Advanced Digestive System Tumor

12/25

Zhuang, Wu

ETER701, NCT04234607: A Study of TQB2450 or Placebo Combined With Anlotinib, Etoposide and Carboplatin Versus Etoposide and Carboplatin in Subjects With Extensive Small Cell Lung Cancer

Not yet recruiting

738

RoW

TQB2450, Anlotinib, Etoposide, Carboplatin, TQB2450（blank）, Anlotinib（blank)

Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Extensive Small Cell Lung Cancer

12/22

NCT06616532: PM8002 in Combination With Paclitaxel Compared With Chemotherapy as Second-line Treatment in Small Cell Lung Cancer

Recruiting

404

RoW

PM8002, Paclitaxel, Topotecan

Biotheus Inc.

SCLC

01/27

12/28

NCT04412564: A Study of TQ-B3101 Capsules in Subjects With Advanced Malignant Tumor

Recruiting

200

RoW

TQ-B3101

Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Advanced Malignant Tumor

03/21

09/21

NCT05221658: A Phase II Clinical Study to Evaluate the Efficacy and Safety of HLX07 Combination Therapy or Monotherapy in Patients With Advanced ESCC

Recruiting

RoW

HLX07+HLX10+ Cisplatin+5-FU, HLX07

Shanghai Henlius Biotech

ESCC or Esophageal Adenosquamous Carcinoma

06/24

08/25

NCT04824079: Keynatinib in Treated Patients with NSCLC and Brain Metastases

Completed

RoW

Keynatinib, TL007

Medolution Ltd.

Non-Small Cell Lung Cancer with EGFR Mutation, Brain Metastases

12/24

NCT05956587: A Study of SI-B003 and BL-B01D1+SI-B003 in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer, Nasopharyngeal Carcinoma and Other Solid Tumors

Recruiting

121

RoW

BL-B01D1, iza-bren, izalontamab brengitecan, BMS-986507, SI-B003

Sichuan Baili Pharmaceutical Co., Ltd., Baili-Bio (Chengdu) Pharmaceutical Co., Ltd.

Non-small Cell Lung Cancer, Nasopharyngeal Carcinoma

11/25

SKB264-II-04, NCT05816252: A Study of SKB264 (MK-2870; Sac-TMT) for the Treatment of Participants With Advanced or Metastatic Non-small Cell Lung Cancer () (MK-2870-003)

Recruiting

498

Europe, RoW

SKB264, MK-2870, Sacituzumab Tirumotecan (Sac-TMT), Pembrolizumab, MK-3475, Carboplatin, Carboplatin for injection, Osimertinib, Osimertinib Mesylate

Klus Pharma Inc., Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.

Non-small Cell Lung Cancer

12/25

10/26

NCT05260385: To Evaluate KC1036 in the Patients with Advanced Digestive System Tumors

Recruiting

1/2

133

RoW

KC1036

Beijing Konruns Pharmaceutical Co., Ltd.

Digestive System Tumors

10/25

12/25

NCT04448379: Efficacy and Safety of JMT101 Combined With Afatinib (or Osimertinib) in Patients With Non-Small Cell Lung Cancer

Recruiting

RoW

JMT101, Afatinib or Osimertinib

Shanghai JMT-Bio Inc., CSPC ZhongQi Pharmaceutical Technology Co., Ltd.

Locally Advanced or Metastatic Non-Small Cell Lung Cancer

12/21

06/22

GQ1005-102, NCT06154343: A Study of GQ1005 in Subjects With HER2-Expressing Advanced Solid Tumors

Recruiting

150

RoW

GQ1005

GeneQuantum Healthcare (Suzhou) Co., Ltd.

HER2 Expressing or Mutated Advanced Malignant Solid Tumors

12/24

07/25

NCT03917043: APG-2449 in Patients With Advanced Solid Tumors

Recruiting

165

RoW

APG-2449, APG-2449 Capsule

Ascentage Pharma Group Inc., Suzhou Yasheng Pharmaceutical Co., Ltd.

Advanced Solid Cancer, Non Small Cell Lung Cancer, Esophageal Cancer, Ovarian Cancer, Malignant Pleural Mesothelioma

12/27

01/28

NCT05513664: Real-World Effectiveness of Osimertinib for Patients With Non-Small Cell Lung Cancer

Not yet recruiting

N/A

RoW

Osimertinib

Shanghai JMT-Bio Inc., CSPC ZhongQi Pharmaceutical Technology Co., Ltd.

Locally Advanced or Metastatic Non-Small Cell Lung Cancer, EGFR Exon20 Insertion Mutations

06/23

08/23

Coordinator

NCT05070455: An Open Label, Multicenter Study to Evaluate the Pharmacokinetics, Efficacy and Safety of ASCENIV™ (IGIV) in Pediatric Subjects With Primary Immunodeficiency Diseases (PIDD)

Recruiting

Asceniv™

ADMA Biologics, Inc.

Primary Immune Deficiency

03/23

06/23

NCT06923891: An Open-Label Study to Evaluate the Efficacy and Tolerability of Xanomeline/Trospium In First Episode/Early Phase Schizophrenia Patients

Not yet recruiting

172

Xanomeline/Trospium, Cobenfy

Vanguard Research Group, Bristol-Myers Squibb

Schizophrenia

10/26

11/26

VRDN-001-302, NCT06179875: An Open-label Study for Non-responders of VRDN-001-101 and VRDN-001-301 (OLE)

Active, not recruiting

143

Europe, US, RoW

Intervention/Treatment

Viridian Therapeutics, Inc.

Thyroid Eye Disease

05/25

07/25

RECOVER, NCT05184335: Safety and Efficacy of Brilaroxazine (RP5063) in Schizophrenia

Recruiting

690

Brilaroxazine, RP5063, Placebo

Reviva Pharmaceuticals

Schizophrenia

02/25

STRIVE, NCT06384547: A Randomized, Controlled, Safety and Tolerability Study of VRDN-001 in Participants with Thyroid Eye Disease (TED)

Active, not recruiting

231

Europe, US, RoW

VRDN-001 10 mg/kg, VRDN-001 3 mg/kg

Viridian Therapeutics, Inc.

Thyroid Eye Disease

05/25

01/26

REVEAL-1, NCT06625411: An Efficacy, Safety, and Tolerability Study of VRDN-003 in Participants with Active Thyroid Eye Disease (TED)

Recruiting

117

VRDN-003, Placebo

Viridian Therapeutics, Inc.

Thyroid Eye Disease

03/26

11/26

REVEAL-2, NCT06625398: An Efficacy, Safety, and Tolerability Study of VRDN-003 in Participants with Chronic Thyroid Eye Disease (TED)

Recruiting

195

VRDN-003, Placebo

Viridian Therapeutics, Inc.

Thyroid Eye Disease

04/26

12/26

THRIVE-2, NCT06021054: An Efficacy, Safety, and Tolerability Study of Veligrotug (VRDN-001), in Participants With Chronic Thyroid Eye Disease (TED)

Active, not recruiting

188

Europe, US, RoW

Veligrotug (VRDN-001), Placebo

Viridian Therapeutics, Inc.

Thyroid Eye Disease

12/24

08/25

NCT04222062: A Study Comparing GLIADEL to Stereotactic Radiosurgery in Metastatic Brain Disease

Recruiting

100

Carmustine 7.7Mg Wafer, GLIADEL

University of Nebraska, Arbor Pharmaceuticals, Inc.

Brain Tumor - Metastatic

12/27

12/28

NCT06107686: A Study of YL202 in Selected Patients with Advanced Solid Tumors

Recruiting

200

RoW

YL202 should be intravenously infused

MediLink Therapeutics (Suzhou) Co., Ltd.

NSCLC, Breast Cancer, HNSCC, Locally Advanced or Metastatic Solid Tumors

11/26

11/28

NCT06057922: A Study YL201 in Patients With Selected Advanced Solid Tumors

Recruiting

1/2

990

RoW

YL201 for Injection

MediLink Therapeutics (Suzhou) Co., Ltd.

Advanced Solid Tumor

10/26

10/28

NCT06186596: Self-Administered Intralesional Injections for Acne

Recruiting

N/A

150

Triamcinolone delivered via injection assistance device

ACOM Labs

Acne Vulgaris

01/24

PRIMA-102, NCT05936970: Prospective, Multi-Center, Observational, Whole Blood Specimen Collection Study in Participants with Rheumatoid Arthritis with Inadequate Response or Intolerance to a DMARD Starting a New BDMARD or TsDMARD Treatment +/- CsDMARD

Recruiting

N/A

1410

Aqtual, Inc.

Rheumatoid Arthritis

06/25

12/25

NCT05100836: SURPASS Impella 5.5 Study

Completed

N/A

1017

Impella 5.5

Abiomed Inc.

Cardiogenic Shock, Acute Decompensated Heart Failure

05/25

Trial + Data / Events

Status

Region

Interventions

Sponsor

Conditions

Primary compl

Study compl

Zhou, Dong

NCT05058482: Non-adhesive Liquid Embolic System in the Embolization of Cerebral Arteriovenous Malformations

Recruiting

N/A

116

RoW

embolism

Suzhou Hengruihongyuan Medical Technology Co. LTD

Intracranial Arteriovenous Malformations

10/23

10/24

NCT04737837: A Real World Study on the Efficacy and Safety of Lacosamide as Add-on Therapy for Focal-onset Epilepsy

Not yet recruiting

N/A

200

RoW

lacosamide, Xinkang

Jiangxi Qingfeng Pharmaceutical Co. Ltd.

Epilepsy, Focal-Onset Seizure

11/21

02/22

yang, jianwei

ENREACH-PDAC-01, NCT05149326: KN046 in Subjects With Advanced Pancreatic Ductal Adenocarcinoma.

Active, not recruiting

408

RoW

KN046, placebo

Jiangsu Alphamab Biopharmaceuticals Co., Ltd

Advanced Pancreatic Ductal Adenocarcinoma

04/24

08/24

Enrolling by invitation

450

RoW

irinotecan, IBI343, paclitaxel

Innovent Biologics (Suzhou) Co. Ltd.

Unresectable or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma

12/26

12/27

NCT05019794: Infigratinib in Subjects With GC or GEJ With FGFR2 Amplification or Other Solid Tumors With Other FGFR Alterations

	NMPA cleared CTA to conduct the Phase 2a trial for metastatic gastric cancer or GE junction adenocarcinoma with FGFR2 gene amplification
	Dec 2020 - Dec 2020: NMPA cleared CTA to conduct the Phase 2a trial for metastatic gastric cancer or GE junction adenocarcinoma with FGFR2 gene amplification

Recruiting

RoW

Infigratinib, BGJ398

LianBio LLC

Gastric Cancer, Gastroesophageal Junction Adenocarcinoma, Solid Tumor

12/22

12/23

Completed

107

RoW

Encorafenib, Braftovi®, PF-07263896, W0090, LGX818, ONO-7702, Cetuximab, Erbitux®, C225, FOLFIRI, Folinic acid + Fluorouracil + Irinotecan

Pierre Fabre Medicament, Merck KGaA, Darmstadt, Germany

BRAF V600E, Metastatic Colorectal Cancer

12/23

12/24

SPH5030-201, NCT06434597: A Clinical Study of SPH5030 Tablets in the Treatment of Her2-positive/Mutated Biliary Tract OR Colorectal Cancer Patients.

Recruiting

RoW

SPH5030

Shanghai Pharmaceuticals Holding Co., Ltd

Biliary Tract or Colorectal Cancer With Her2-positive/Mutated

12/26

NCT05879055: A Study of PM8002 in Combination With Chemotherapy in Patients With NEN

Recruiting

RoW

PM8002, FOLFIRI

Biotheus Inc.

Neuroendocrine Neoplasm

01/27

01/28

KL264-01, NCT04152499: Phase I-II, FIH, TROP2 ADC, Advanced Unresectable/Metastatic Solid Tumors, Refractory to Standard Therapies

Active, not recruiting

1/2

1410

Canada, US, RoW

SKB264, MK-2870, Sacituzumab Tirumotecan (Sac-TMT)

Klus Pharma Inc.

Epithelial Ovarian Cancer, Gastric Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma, Urothelial Carcinoma, Non-Small Cell Lung Cancer, Small-Cell Lung Cancer, Endometrial Carcinoma, Head and Neck Squamous Cell Carcinoma, Breast Cancer, Cervical Cancer

12/25

07/26

KYM901, NCT04805307: Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy, Phase 1 Study of CMG901

Completed

176

RoW

CMG901

Keymed Biosciences Co.Ltd

Advanced Solid Tumor, Gastric Cancer(Including Gastroesophageal Junction Adenocarcinoma), Pancreatic Cancer

04/24

CIBI343A101, NCT05458219: A First-in-human Study of IBI343 in Subjects With Locally Advanced Unresectable or Metastatic Solid Tumors

Recruiting

470

US, RoW

IBI343

Innovent Biologics (Suzhou) Co. Ltd., Fortvita Biologics (USA)Inc., TigerMed

Locally Advanced Unresectable or Metastatic Solid Tumors

12/25

CIBI363A103, NCT06468098: A Study of IBI363 in Subjects With Advanced Malignancies

Recruiting

556

RoW

IBI363 + chemotherapy, IBI363 + Investigator's Choice SOC

Innovent Biologics (Suzhou) Co. Ltd.

Advanced Malignancies

06/25

12/26

NCT05946226: A Phase I Trial to Evaluate the Safety of IMC002 in Advanced Digestive System Tumors

Recruiting

RoW

IMC002 injection, Autologous Claudin 18.2 specific CAR-T cell injection

Suzhou Immunofoco Biotechnology Co., Ltd

Advanced Digestive System Tumor

12/25

Zhuang, Wu

ETER701, NCT04234607: A Study of TQB2450 or Placebo Combined With Anlotinib, Etoposide and Carboplatin Versus Etoposide and Carboplatin in Subjects With Extensive Small Cell Lung Cancer

Not yet recruiting

738

RoW

TQB2450, Anlotinib, Etoposide, Carboplatin, TQB2450（blank）, Anlotinib（blank)

Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Extensive Small Cell Lung Cancer

12/22

NCT06616532: PM8002 in Combination With Paclitaxel Compared With Chemotherapy as Second-line Treatment in Small Cell Lung Cancer

Recruiting

404

RoW

PM8002, Paclitaxel, Topotecan

Biotheus Inc.

SCLC

01/27

12/28

NCT04412564: A Study of TQ-B3101 Capsules in Subjects With Advanced Malignant Tumor

Recruiting

200

RoW

TQ-B3101

Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Advanced Malignant Tumor

03/21

09/21

NCT05221658: A Phase II Clinical Study to Evaluate the Efficacy and Safety of HLX07 Combination Therapy or Monotherapy in Patients With Advanced ESCC

Recruiting

RoW

HLX07+HLX10+ Cisplatin+5-FU, HLX07

Shanghai Henlius Biotech

ESCC or Esophageal Adenosquamous Carcinoma

06/24

08/25

NCT04824079: Keynatinib in Treated Patients with NSCLC and Brain Metastases

Completed

RoW

Keynatinib, TL007

Medolution Ltd.

Non-Small Cell Lung Cancer with EGFR Mutation, Brain Metastases

12/24

NCT05956587: A Study of SI-B003 and BL-B01D1+SI-B003 in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer, Nasopharyngeal Carcinoma and Other Solid Tumors

Recruiting

121

RoW

BL-B01D1, iza-bren, izalontamab brengitecan, BMS-986507, SI-B003

Sichuan Baili Pharmaceutical Co., Ltd., Baili-Bio (Chengdu) Pharmaceutical Co., Ltd.

Non-small Cell Lung Cancer, Nasopharyngeal Carcinoma

11/25

SKB264-II-04, NCT05816252: A Study of SKB264 (MK-2870; Sac-TMT) for the Treatment of Participants With Advanced or Metastatic Non-small Cell Lung Cancer () (MK-2870-003)

Recruiting

498

Europe, RoW

SKB264, MK-2870, Sacituzumab Tirumotecan (Sac-TMT), Pembrolizumab, MK-3475, Carboplatin, Carboplatin for injection, Osimertinib, Osimertinib Mesylate

Klus Pharma Inc., Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.

Non-small Cell Lung Cancer

12/25

10/26

NCT05260385: To Evaluate KC1036 in the Patients with Advanced Digestive System Tumors

Recruiting

1/2

133

RoW

KC1036

Beijing Konruns Pharmaceutical Co., Ltd.

Digestive System Tumors

10/25

12/25

NCT04448379: Efficacy and Safety of JMT101 Combined With Afatinib (or Osimertinib) in Patients With Non-Small Cell Lung Cancer

Recruiting

RoW

JMT101, Afatinib or Osimertinib

Shanghai JMT-Bio Inc., CSPC ZhongQi Pharmaceutical Technology Co., Ltd.

Locally Advanced or Metastatic Non-Small Cell Lung Cancer

12/21

06/22

GQ1005-102, NCT06154343: A Study of GQ1005 in Subjects With HER2-Expressing Advanced Solid Tumors

Recruiting

150

RoW

GQ1005

GeneQuantum Healthcare (Suzhou) Co., Ltd.

HER2 Expressing or Mutated Advanced Malignant Solid Tumors

12/24

07/25

NCT03917043: APG-2449 in Patients With Advanced Solid Tumors

Recruiting

165

RoW

APG-2449, APG-2449 Capsule

Ascentage Pharma Group Inc., Suzhou Yasheng Pharmaceutical Co., Ltd.

Advanced Solid Cancer, Non Small Cell Lung Cancer, Esophageal Cancer, Ovarian Cancer, Malignant Pleural Mesothelioma

12/27

01/28

NCT05513664: Real-World Effectiveness of Osimertinib for Patients With Non-Small Cell Lung Cancer

Not yet recruiting

N/A

RoW

Osimertinib

Shanghai JMT-Bio Inc., CSPC ZhongQi Pharmaceutical Technology Co., Ltd.

Locally Advanced or Metastatic Non-Small Cell Lung Cancer, EGFR Exon20 Insertion Mutations

06/23

08/23

Coordinator

NCT05070455: An Open Label, Multicenter Study to Evaluate the Pharmacokinetics, Efficacy and Safety of ASCENIV™ (IGIV) in Pediatric Subjects With Primary Immunodeficiency Diseases (PIDD)

Recruiting

Asceniv™

ADMA Biologics, Inc.

Primary Immune Deficiency

03/23

06/23

NCT06923891: An Open-Label Study to Evaluate the Efficacy and Tolerability of Xanomeline/Trospium In First Episode/Early Phase Schizophrenia Patients

Not yet recruiting

172

Xanomeline/Trospium, Cobenfy

Vanguard Research Group, Bristol-Myers Squibb

Schizophrenia

10/26

11/26

VRDN-001-302, NCT06179875: An Open-label Study for Non-responders of VRDN-001-101 and VRDN-001-301 (OLE)

Active, not recruiting

143

Europe, US, RoW

Intervention/Treatment

Viridian Therapeutics, Inc.

Thyroid Eye Disease

05/25

07/25

RECOVER, NCT05184335: Safety and Efficacy of Brilaroxazine (RP5063) in Schizophrenia

Recruiting

690

Brilaroxazine, RP5063, Placebo

Reviva Pharmaceuticals

Schizophrenia

02/25

STRIVE, NCT06384547: A Randomized, Controlled, Safety and Tolerability Study of VRDN-001 in Participants with Thyroid Eye Disease (TED)

Active, not recruiting

231

Europe, US, RoW

VRDN-001 10 mg/kg, VRDN-001 3 mg/kg

Viridian Therapeutics, Inc.

Thyroid Eye Disease

05/25

01/26

REVEAL-1, NCT06625411: An Efficacy, Safety, and Tolerability Study of VRDN-003 in Participants with Active Thyroid Eye Disease (TED)

Recruiting

117

VRDN-003, Placebo

Viridian Therapeutics, Inc.

Thyroid Eye Disease

03/26

11/26

REVEAL-2, NCT06625398: An Efficacy, Safety, and Tolerability Study of VRDN-003 in Participants with Chronic Thyroid Eye Disease (TED)

Recruiting

195

VRDN-003, Placebo

Viridian Therapeutics, Inc.

Thyroid Eye Disease

04/26

12/26

THRIVE-2, NCT06021054: An Efficacy, Safety, and Tolerability Study of Veligrotug (VRDN-001), in Participants With Chronic Thyroid Eye Disease (TED)

Active, not recruiting

188

Europe, US, RoW

Veligrotug (VRDN-001), Placebo

Viridian Therapeutics, Inc.

Thyroid Eye Disease

12/24

08/25

NCT04222062: A Study Comparing GLIADEL to Stereotactic Radiosurgery in Metastatic Brain Disease

Recruiting

100

Carmustine 7.7Mg Wafer, GLIADEL

University of Nebraska, Arbor Pharmaceuticals, Inc.

Brain Tumor - Metastatic

12/27

12/28

NCT06107686: A Study of YL202 in Selected Patients with Advanced Solid Tumors

Recruiting

200

RoW

YL202 should be intravenously infused

MediLink Therapeutics (Suzhou) Co., Ltd.

NSCLC, Breast Cancer, HNSCC, Locally Advanced or Metastatic Solid Tumors

11/26

11/28

NCT06057922: A Study YL201 in Patients With Selected Advanced Solid Tumors

Recruiting

1/2

990

RoW

YL201 for Injection

MediLink Therapeutics (Suzhou) Co., Ltd.

Advanced Solid Tumor

10/26

10/28

NCT06186596: Self-Administered Intralesional Injections for Acne

Recruiting

N/A

150

Triamcinolone delivered via injection assistance device

ACOM Labs

Acne Vulgaris

01/24

Recruiting

N/A

1410

Aqtual, Inc.

Rheumatoid Arthritis

06/25

12/25

NCT05100836: SURPASS Impella 5.5 Study

Completed

N/A

1017

Impella 5.5

Abiomed Inc.

Cardiogenic Shock, Acute Decompensated Heart Failure

05/25

Download Options



	Diseases Companies Products Productz Mechanisms of Action Sites